Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental conditions in both children and adults, affecting approximately 5–7% of children and 2–5% of adults globally. In SA's private healthcare system, ADHD management presents a specific regulatory challenge: stimulant medications — the most effective pharmacological treatment — are Schedule 6 controlled substances, requiring psychiatrist prescribing authority and significantly influencing the specialist consultation benefit structure. Understanding the regulatory framework, the coverage architecture, and the real annual cost of optimally managed ADHD is essential for families and adults navigating the system.
What Is ADHD?
ADHD is characterised by persistent, impairing symptoms of inattention, hyperactivity, and impulsivity that are inappropriate for developmental level and cause functional impairment across at least two settings (e.g., home and school; home and work). Three subtypes:
- Predominantly Inattentive (ADHD-I): Difficulty sustaining attention, distractibility, forgetfulness, poor organisation; not primarily hyperactive. Often missed in girls and adults.
- Predominantly Hyperactive-Impulsive (ADHD-HI): Restlessness, excessive talking, difficulty waiting, impulsive actions; most prominent in young children.
- Combined Presentation (ADHD-C): Both inattentive and hyperactive-impulsive symptoms.
ADHD is a neurobiological condition — not a behavioural failure or a result of poor parenting. It has a strong genetic component and reflects underlying differences in dopaminergic and noradrenergic neurotransmitter systems.
Common co-existing conditions that must be assessed alongside ADHD: anxiety disorder, depression, specific learning disorder (dyslexia, dyscalculia), oppositional defiant disorder (ODD), sleep disorders, and — in adults — substance use disorders. These co-morbidities influence medication choice and the benefit utilisation profile.
The Regulatory Framework: Why a Psychiatrist Is Required
Methylphenidate (Ritalin, Concerta, Rubifen SR) is a Schedule 6 controlled substance in South Africa. Under SA pharmaceutical law, Schedule 6 medications: - Require a psychiatrist, paediatrician, or neurologist for initial prescription - Require a triplicate prescription (three copies; one retained by pharmacy, one sent to SAHPRA, one held by prescriber) - Have strict dispensing limits (monthly supply only; no repeats)
This regulatory requirement has a direct impact on the benefit structure: the initial diagnosis and prescription must come from a specialist, not a GP. Subsequent renewals may in some provinces be managed by a GP on the specialist's instruction, but initial authority rests with a psychiatrist (for adults) or paediatrician/child psychiatrist (for children).
This means that ADHD management consumes the specialist consultation benefit more significantly than conditions managed by GPs. Quarterly psychiatrist review for medication monitoring is standard practice — four specialist visits per year is the baseline for well-managed ADHD.
Medications: The Treatment Landscape
Stimulant medications — first-line:
Methylphenidate IR (Ritalin 5/10mg): Short-acting (4–6 hours); requires 2–3 doses per day; covers school hours but may require afternoon dose for homework. Monthly cost: approximately R400. Available as generic.
Methylphenidate ER — Concerta 18/27/36/54mg: Extended-release formulation (10–12 hours); once-daily; covers full school/work day. Preferred for most school-age children and adults due to adherence and consistency. Monthly cost: approximately R800. Some formulary cover but may require non-formulary motivation for specific dose.
Methylphenidate ER — Rubifen SR / other ER generics: Extended-release generic alternatives; lower cost than Concerta; 8-hour duration. Monthly cost: R600–R700.
Lisdexamfetamine (Vyvanse): Amphetamine prodrug; once-daily; 12–14 hour duration; lower abuse potential due to prodrug mechanism. SAHPRA registration and SA availability require verification. Monthly cost: approximately R1,200.
Non-stimulant medications — second-line:
Atomoxetine (Strattera): Selective noradrenaline reuptake inhibitor; once-daily; non-stimulant; effective for ADHD with co-morbid anxiety or tic disorder where stimulants may exacerbate symptoms; slower onset (4–6 weeks); black box warning for suicidality risk in paediatric patients. Monthly cost: approximately R900.
Clonidine: Alpha-2 agonist; useful adjunct for hyperactivity, tics, sleep, and aggression. Inexpensive (~R200/month).
Non-Pharmacological Interventions
Medication is most effective when combined with structured psychological and behavioural support:
For children: Parent training in behaviour management (PTBM) is a first-line intervention, particularly for younger children. The child's school should be engaged — classroom accommodations (preferential seating, extended time in examinations, reduced distraction) are important components of management.
For adults: CBT for adults with ADHD addresses compensatory skill building (planning, organisation, time management, emotional regulation). Academic/occupational coaching may also be helpful.
Both parent training and CBT for ADHD can be funded through the mental health psychology benefit — typically 10–20 sessions/year.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Child — methylphenidate IR + paediatrician review (4×/year) | R10,000 – R20,000 |
| Child — Concerta + paediatrician + psychologist | R20,000 – R35,000 |
| Adult — Concerta/Vyvanse + psychiatrist (4×/year) | R18,000 – R35,000 |
| Complex — multiple co-morbidities + neuropsychological assessment | R30,000 – R55,000 |
Neuropsychological Assessment: The Hidden Cost
Comprehensive neuropsychological assessment (IQ testing, attention testing, academic achievement testing) is often recommended before or alongside ADHD diagnosis in complex cases. Cost: R4,000–R10,000 per assessment. Coverage under the diagnostic investigation benefit varies significantly.
Gap Cover Relevance: Low
ADHD rarely generates hospitalisation. Gap cover is not a primary recommendation. Specialist consultation shortfalls are modest — psychiatrist consultations carry lower shortfall risk than surgical specialties.
Plan Selection: What Matters
- Psychiatrist consultation benefit (4 visits/year minimum)
- Schedule 6 stimulant medication formulary access (Concerta; Vyvanse if available)
- Psychology benefit for CBT or parent training (10+ sessions/year needed)
- Neuropsychological assessment benefit under diagnostic investigations
- Mental health benefit for co-morbid anxiety or depression if present
Talk to Eldon
See which plans pay for ADHD →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).